CABA-201 Clinical Trials
3 recruitingBiologic
Phase 13Phase 23
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Phase 1Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio28 enrolled23 locationsNCT06121297
Recruiting
Phase 1Phase 2
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Pemphigus Vulgaris
Cabaletta Bio40 enrolled13 locationsNCT04422912